HOME >> BIOLOGY >> NEWS
UCSF-led study offers insight into cancer development, resistance to therapy: finding focuses on Ras oncogene

UCSF-led scientists have determined that under certain conditions the Ras oncogene, a key culprit in many cancers, suppresses the function of the p53 tumor-suppressor gene, offering an important insight into the development of some cancers, and an explanation for why some cancers are resistant to radiation therapy. The finding is published in the current issue of Cell.

The Ras gene is part of a molecular pathway that transmits messages for cell growth - an essential component of cell function - from the surface of the cell into the cell's nucleus. But when mutated, as it is in a third of cancers, Ras functions like a gas pedal jammed to the floor, driving a cell into growth and replication overdrive. If coupled with enough other mutations causing destabilization of the cell's growth controls, the Ras oncogene can contribute to the development of cancer.

While Ras's direct role in many cancers has been known, the new finding suggests that, by regulating the p53 tumor-suppressor gene, Ras may play an indirect role in many more, says the co-lead author of the study, Stefan Ries, PhD, a postdoctoral fellow in the laboratory of senior author Frank McCormick, PhD, director of the UCSF Comprehensive Cancer Center.

"Ras's suppression of p53 could play an important role in inactivating the tumor suppressor during the early stages of some tumor development. This may be particularly true in colon cancers," says Ries.

The p53 tumor-suppressor gene is one of several genes that serve as a protector of a cell's DNA. If DNA has been damaged, as can occur during DNA replication and cell division or as a result of an environmental injury, the gene receives a signal that it should halt the cell's cycle of growth. If the cell repairs itself, p53 releases its brake; but if the damage remains, p53 induces cell death, which prevents the cell from continued growth and, ultimately, the dividing into daughter cells containing its damaged DNA. Mutations are a form of DNA damag
'"/>

Contact: Jennifer O'Brien
jobrien@pubaff.ucsf.edu
415-476-2557
University of California - San Francisco
23-Oct-2000


Page: 1 2 3

Related biology news :

1. UCSF-led study raises doubts about marrow cell treatment for brain, heart
2. UCSF-led team reports new test improves detection of prions in animals
3. UCSF-led study points to pivotal, early event in cancer development
4. Student science contest participation influences study, career choices, alumni say
5. New study shows hope for treating inhalant abuse
6. International study findings link acne-like rash to effectiveness of new targeted cancer treatment
7. Cigarette smoke causes breaks in DNA and defects to a cells chromosomes, Pitt study finds
8. New study indicates arsenic could be suitable as first-line treatment in type of leukaemia
9. Phase II trials of second-generation antisense cancer drug planned following successful early study
10. Preclinical safety study shows adipose-derived stem cells improve heart function after heart attack
11. Indiana University, EPA to study airborne PCBs

Post Your Comments:
(Date:12/17/2014)... RALEIGH, N.C. , Dec. 16, 2014 ... has licensed its PerformTek biometric technology to industry leaders ... their highly accurate, clinically validated, biometric wearable products. These ... January 6-9 in Las Vegas . ... the technology is accurate, flexible and robust – with ...
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... to their offering. One major ... technology. With continuous advances in technology, it is ... standard that meets the needs and expectations of ...
(Date:12/10/2014)... 8, 2014 You,ve been here before: you desperately ... remember your password, site key or the answer to your ... grade teacher? Today, Hoyos Labs , ... that will finally put an end to the frustration that ... . 1U leverages a user,s smartphone to acquire his ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
(Date:12/17/2014)... , Dec. 17, 2014 CASI Pharmaceuticals, Inc. ... to the acquisition, development and commercialization of innovative therapeutics ... global market with a primary commercial focus on ... been granted a Type C meeting with the U.S. ... will be held in February 2015.  During this meeting ...
(Date:12/15/2014)... , Dec. 15, 2014 Organovo ... biology company focused on delivering breakthrough 3D bioprinting ... industry and collaborators of its exVive3D TM ... widely available in full commercial release on November ... field, resulting in several awards for innovation. ...
(Date:12/13/2014)... MaRS and Virgin Unite Canada, the non-profit foundation of the ... support Canadian entrepreneurs tackling social and environmental challenges. Today, Sir ... MaRS Centre to announce the new partnership, which includes the ... has $1 million in seed capital provided by Virgin Unite ... Innovation Foundation, founded by Alison Lawton . ...
(Date:12/13/2014)... According to population studies: “North Carolina ... and 2030." If a population explosion like that actually ... state in the country. , To that end, North ... of North Carolina Forum on December 16th to ask ... necessary infrastructure in place? Enough clean water? And will ...
Breaking Biology Technology:CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 2Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 3MaRS and Virgin Unite partner to invest in business as a force for good 2MaRS and Virgin Unite partner to invest in business as a force for good 3North Carolina Chamber of Commerce: Asking Questions & Gathering Answers with a Futurist 2
Cached News: